Bococizumab is a novel anti-PCSK9 antibody efficiently developed to treat hypercholesterolemia. It therapeutic agent interacts with the PCSK9 protein, a essential regulator of cholesterol concentrations. By blocking https://www.targetmol.com/compound/bococizumab